Format

Send to

Choose Destination
Leuk Lymphoma. 2015;56(9):2637-42. doi: 10.3109/10428194.2015.1012714. Epub 2015 Mar 14.

Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia.

Author information

1
a Department of Hematology , Niguarda Ca' Granda Hospital , Milano , Italy.
2
b Department of Hematology , University of Torino , Torino , Italy.
3
c Department of Hematology , AO Città della Salute e della Scienza di Torino , San Giovanni Battista, Torino , Italy.
4
d Division of Hematology, Department of Translational Medicine , Amedeo Avogadro University of Eastern Piedmont , Novara , Italy.
5
e Department of Hematology , IRCCS Policlinico San Matteo , Pavia , Italy.
6
f Department of Clinical and Experimental Medicine , University of Pisa , Pisa , Italy.
7
g Department of Hematology , AO Spedali Civili , Brescia , Italy.
8
h Department of Hematology , AOU Ospedali Riuniti , Ancona , Italy.
9
i Department of Hematology , IRCCS Ospedale Maggiore Policlinico, Università degli Studi di Milano , Milano , Italy.
10
j Department of Cell Therapy and Hematology , Ospedale San Bortolo , Vicenza , Italy.
11
k Department of Hematology , AO Universitaria S. Maria Misericordia , Udine , Italy.
12
l Department of Oncology and Hematology , General Hospital , Nocera Inferiore , Italy.
13
m Department of Internal Medicine , Valduce Hospital , Como , Italy.
14
n Department of Hematology , AO di Cosenza , Cosenza , Italy.

Abstract

According to the European Society for Medical Oncology and National Comprehensive Cancer Network guidelines on Waldenström macroglobulinemia, bendamustine (B) may be considered a suitable therapeutic option. To address the role of B in combination with rituximab (BR), we analyzed the outcome of 71 patients with relapsed/refractory disease, median age 72 years, treated with R 375 mg/m(2) day 1 and B days 1 and 2 (dosage ranging from 50 to 90 mg/m(2)). Patients had previously received a median number of 2 lines of treatment (range 1-5). Overall and major response rates were 80.2% and 74.6%. Major toxicity was grade 3/4 neutropenia occurring in 13% of courses. There was no significant association between baseline features or patients' characteristics and response achievement. Median progression-free survival was not reached after a median follow-up of 19 months (range 3-54). None of the patients developed aggressive lymphoma or secondary myelodysplastic syndrome/acute myeloid leukemia. BR was found to be an active and well-tolerated salvage regimen leading to rapid disease control.

KEYWORDS:

Bendamustine; Waldenström macroglobulinemia; refractory; relapsed; rituximab; salvage

PMID:
25651423
DOI:
10.3109/10428194.2015.1012714
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center